Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective-Reference-Cited by-同舟云学术

Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective

Published:2019-12 Issue: Volume:20 Page:95-102
ISSN:2212-1099
Container-title:Value in Health Regional Issues
language:en
Short-container-title:Value in Health Regional Issues

Author:

Borba Helena H.L.,Rochau Ursula,Wiens Astrid,Sroczynski Gaby,Siebert Uwe,Ferreira Vinicius L.,Minowa Eimy,Pontarolo Roberto

Funder

Coordination for the Improvement of Higher Level Personnel

National Council for Scientific and Technological Development

Publisher

Elsevier BV

Subject

Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Economics, Econometrics and Finance (miscellaneous)

Reference35 articles.

1. Disease burden of chronic hepatitis C in Brazil;Ferreira;Braz J Infect Dis,2015

2. Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection;Fernandez-Yunquera;Rev Esp Quimioter,2013

3. Chronic hepatitis C: this and the new era of treatment;Bertino;World J Hepatol,2016

4. Chronic hepatitis C: an overview of evidence on epidemiology and management from a Brazilian perspective;Castro;Int J Hepatol,2015

5. Barriers to directly acting antiviral agent use for chronic hepatitis C in South and South East Asia;Ahmed;SM J Hepat Res Treat,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study;BMJ Open;2022-06

2. Telaprevir more cost effective than boceprevir in triple therapy;PharmacoEconomics & Outcomes News;2019-06